Skip to main content

Table 3 Association of SLC30A8 common haplotypes and diplotypes with GADA negative diabetes among combined races and Indian subjects

From: Contribution of SLC30A8 variants to the risk of type 2 diabetes in a multi-ethnic population: a case control study

rs13266634, rs1995222

Combined races

Indians

Frequency

P-value

OR (95% CI)

Frequency

P-value

OR (95% CI)

Control

GADA negative diabetes

Control

GADA negative diabetes

Haplotypes

AT

0.44

0.39

0.10

0.83(0.67–1.03)

0.23

0.20

0.28

0.78(0.50–1.23)

CG

0.21

0.32

8.6 × 10 -5

1.67(1.29–2.15)

0.36

0.51

0.001

1.93(1.31–2.85)

GT

0.17

0.14

0.08

0.77(0.58–1.03)

0.22

0.12

0.008

0.51(0.31–0.84)

AC

0.14

0.13

0.59

0.92(0.67–1.25)

0.15

0.15

0.91

0.97(0.57–1.65)

Diplotypes

CG-CG

0.21

0.32

8.6 × 10 -5

1.67(1.29–2.15)

0.36

0.51

0.001

1.93(1.31–2.85)

CG-AT

0.24

0.22

0.36

0.89(0.69–1.14)

0.20

0.16

0.15

0.70(0.43–1.13)

CG-GT

0.14

0.11

0.09

0.76(0.55–1.05)

0.20

0.11

0.005

0.48(0.29–0.80)

CG-AC

0.12

0.11

0.62

0.92(0.67–1.27)

0.14

0.13

0.94

1.02(0.58–1.79)

GT-AT

0.08

0.07

0.62

0.90(0.60–1.36)

0.02

0.01

0.30

0.48(0.12–1.91)

AC-AT

0.07

0.04

0.001

0.43(0.27–0.70)

0.006

0.01

NA

NA

  1. Controlled for age, gender, race and BMI. The outliers (studentized residual is greater than 2.0 or less than−2.0) were excluded. GADA, glutamic acid decarboxylase antibodies.